BioCentury
ARTICLE | Company News

Spark elaborates on proposed Luxturna value-based pricing model

February 13, 2019 11:23 PM UTC

Spark Therapeutics Inc. (NASDAQ:ONCE) Chief Commercial Officer Ron Philip disclosed additional details on the company's value-based pricing proposal to CMS for Luxturna voretigene neparvovec-rzyl during the BIO CEO and Investor Conference in New York on Feb. 11.

The vision loss gene therapy has a wholesale acquisition cost of $425,000 per eye, or $850,000 per patient for the majority who will need both eyes treated...

BCIQ Company Profiles

Spark Therapeutics Inc.